JCR Pharmaceuticals Co., Ltd.
13
1
5
7
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
0.0%
0 terminated/withdrawn out of 13 trials
100.0%
+13.5% vs industry average
31%
4 trials in Phase 3/4
14%
1 of 7 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (13)
A Phase III Study of JR-141 in Patients With Mucopolysaccharidosis II (STARLIGHT)
Role: lead
An Extension Study of JR-141 to Evaluate the Long-term Safety and Efficacy in MPS II (Hunter Syndrome) Subjects
Role: lead
An Open-label Phase I/II Study of JR-446 in Mucopolysaccharidosis Type IIIB
Role: lead
An Extension Study of JR-171-101 Study in Patients With Mucopolysaccharidosis Type I (MPS I)
Role: lead
Phase I/II Study of JR-441 in Patients With Mucopolysaccharidosis Type IIIA
Role: lead
A Study of JR-141 in Patients With Mucopolysaccharidosis II (BR21)
Role: lead
An Extension Study of JR-141-BR21 in Patients With Mucopolysaccharidosis II
Role: lead
An Extension Study of JR-141 in Patients With Mucopolysaccharidosis Type II
Role: lead
A Study of JR-171 in Patients With Mucopolysaccharidosis I
Role: lead
A Study of JR-141 in Patients With Mucopolysaccharidosis II
Role: lead
A Study of JR-141 in Patients With Mucopolysaccharidosis Type II
Role: lead
A Phase III Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)
Role: collaborator
A Long-term Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)
Role: collaborator
All 13 trials loaded